Epigenomics AG gets CE-IVD Mark for Lung Cancer Test Epi proLung
Epigenomics AG gets CE-IVD Mark for Lung Cancer Test Epi proLung(R)
Berlin (Germany) and Germantown, MD (U.S.A.), December 19, 2017 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY, "Company") announced today that it has received CE-IVD mark for its blood-based lung cancer test Epi proLung.
Epi proLung is a highly innovative lung cancer test based on the combination of Epigenomics' proprietary DNA methylation biomarkers. The development of the assay was partly funded by the European Commission within the framework of the Horizon 2020 program.
Lung cancer remains one of the world's most common and deadliest forms of cancer. Most lung cancers have already spread widely and are at an advanced stage when detected. Earlier detection, less risk to the patient from diagnostic methods, more successful therapies and lower treatment costs represent a high unmet medical need. Nevertheless, no European screening recommendation or guidelines have been issued to date to screen patients with an elevated risk for lung cancer.
Greg Hamilton, CEO of Epigenomics AG stated: "Lung cancer is a deadly disease for which there are limited diagnostic options. The CE-IVD mark for Epi proLung is our first step in providing additional testing options. We will continue to enhance the product as we learn more through clinical studies in the future."About Epigenomics
Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics' lead product, Epi proColon(R), is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, and China and selected other countries. Epi proLung(R), a blood-based test for lung cancer detection, has received CE mark in Europe.
For more information, visit www.epigenomics.com.
Contact: Epigenomics AG, Investor Relations, Peter Vogt, Geneststrasse 5, 10829 Berlin, Tel +49 (0) 30 24345 386, Fax +49 (0) 30 24345 555, E-Mail: email@example.com
This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
19.12.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.deLanguage: English Company: Epigenomics AG Geneststraße 5 10829 Berlin
Germany Phone: +49 30 24345-0 Fax: +49 30 24345-555 E-mail: firstname.lastname@example.org Internet: www.epigenomics.com ISIN: DE000A11QW50 WKN: A11QW5 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service